Market Cap | 2.91B | P/E | - | EPS this Y | -28.30% | Ern Qtrly Grth | 8.20% |
Income | -20.76M | Forward P/E | 27.13 | EPS next Y | 16.10% | 50D Avg Chg | -8.00% |
Sales | 1.08B | PEG | 2.57 | EPS past 5Y | -17.81% | 200D Avg Chg | 7.00% |
Dividend | N/A | Price/Book | 2.50 | EPS next 5Y | 12.00% | 52W High Chg | -43.00% |
Recommedations | 2.40 | Quick Ratio | 1.99 | Shares Outstanding | 45.99M | 52W Low Chg | 40.00% |
Insider Own | 1.57% | ROA | -0.99% | Shares Float | 42.60M | Beta | 0.83 |
Inst Own | 103.20% | ROE | -1.76% | Shares Shorted/Prior | 2.28M/1.98M | Price | 64.58 |
Gross Margin | 41.63% | Profit Margin | -1.92% | Avg. Volume | 426,117 | Target Price | 44.50 |
Oper. Margin | 1.17% | Earnings Date | Oct 31 | Volume | 1,388,781 | Change | 4.67% |
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
JP Morgan | Neutral | Aug 23, 24 |
Wells Fargo | Equal-Weight | Aug 2, 24 |
B of A Securities | Buy | Aug 2, 24 |
Barclays | Equal-Weight | Aug 2, 24 |
Benchmark | Buy | Jul 15, 24 |
Benchmark | Buy | May 3, 24 |
Benchmark | Buy | Apr 30, 24 |
Benchmark | Buy | Feb 9, 24 |
Wells Fargo | Equal-Weight | Feb 9, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
LIPPS RANDALL A | CHAIRMAN, PRESIDENT.. CHAIRMAN, PRESIDENT AND CEO | Jun 08 | Buy | 73.76 | 4,000 | 295,040 | 318,768 | 06/12/23 |
Seidelmann Scott Peter | EVP, CHIEF COMMERCIA.. EVP, CHIEF COMMERCIAL OFFICER | Nov 28 | Sell | 51.46 | 1,793 | 92,268 | 38,996 | 11/30/22 |
Kuipers Peter J. | EXECUTIVE V P& CFO EXECUTIVE V P& CFO | Aug 26 | Option | 61.58 | 15,500 | 954,490 | 76,826 | 08/30/22 |
Kuipers Peter J. | EXECUTIVE V P& CFO EXECUTIVE V P& CFO | Aug 26 | Sell | 108.52 | 15,500 | 1,682,060 | 61,326 | 08/30/22 |
Kuipers Peter J. | EXECUTIVE V P& CFO EXECUTIVE V P& CFO | Aug 22 | Option | 44.25 | 11,000 | 486,750 | 72,326 | 08/24/22 |
Kuipers Peter J. | EXECUTIVE V P& CFO EXECUTIVE V P& CFO | Aug 22 | Sell | 105.93 | 11,000 | 1,165,230 | 61,326 | 08/24/22 |
LIPPS RANDALL A | CHAIRMAN, PRESIDENT.. CHAIRMAN, PRESIDENT AND CEO | Aug 16 | Sell | 111.04 | 13,000 | 1,443,520 | 302,049 | 08/18/22 |
Seidelmann Scott Peter | EVP, CHIEF COMMERCIA.. EVP, CHIEF COMMERCIAL OFFICER | Jun 15 | Sell | 109.86 | 3,765 | 413,623 | 40,789 | 06/17/22 |
Seidelmann Scott Peter | EVP, Chief Commercia.. EVP, Chief Commercial Officer | Mar 14 | Sell | 133.11 | 2,525 | 336,103 | 48,380 | 03/16/22 |
PARRISH MARK W | Director Director | Mar 10 | Option | 14.87 | 2,000 | 29,740 | 42,558 | 03/11/22 |
PARRISH MARK W | Director Director | Feb 18 | Option | 14.87 | 3,000 | 44,610 | 40,558 | 02/22/22 |
JOHNSTON DAN S | EVP & Chief Legal &.. EVP & Chief Legal & Admin | Dec 15 | Sell | 177.06 | 1,063 | 188,215 | 25,831 | 12/16/21 |
Seidelmann Scott Peter | EVP, Chief Commercia.. EVP, Chief Commercial Officer | Dec 15 | Sell | 177.24 | 3,628 | 643,027 | 33,632 | 12/16/21 |
Kuipers Peter J. | Executive V P& CFO Executive V P& CFO | Dec 08 | Option | 0 | 5,640 | 59,592 | 12/08/21 | |
Kuipers Peter J. | Executive V P& CFO Executive V P& CFO | Dec 08 | Sell | 181.15 | 8,517 | 1,542,855 | 51,075 | 12/08/21 |
SPEARS JOSEPH BRIAN | Chief Accounting Off.. Chief Accounting Officer & VP | Dec 07 | Sell | 180.98 | 8,155 | 1,475,892 | 9,399 | 12/08/21 |
JOHNSTON DAN S | EVP & Chief Legal &.. EVP & Chief Legal & Admin | Oct 26 | Option | 0 | 10,451 | 39,427 | 10/27/21 | |
JOHNSTON DAN S | EVP & Chief Legal &.. EVP & Chief Legal & Admin | Oct 26 | Sell | 170 | 10,451 | 1,776,670 | 28,976 | 10/27/21 |
Kuipers Peter J. | Executive V P& CFO Executive V P& CFO | May 18 | Sell | 135.59 | 2,395 | 324,738 | 69,454 | 05/18/21 |
LIPPS RANDALL A | Chairman, President.. Chairman, President and CEO | Dec 09 | Option | 0 | 25,000 | 177,116 | 12/09/20 | |
LIPPS RANDALL A | Chairman, President.. Chairman, President and CEO | Dec 09 | Sell | 122.61 | 25,000 | 3,065,250 | 152,116 | 12/09/20 |
LIPPS RANDALL A | Chairman, President.. Chairman, President and CEO | Dec 08 | Option | 0 | 17,500 | 152,767 | 12/08/20 | |
LIPPS RANDALL A | Chairman, President.. Chairman, President and CEO | Dec 08 | Sell | 110.8 | 17,500 | 1,939,000 | 152,116 | 12/08/20 |
LIPPS RANDALL A | Chairman, President.. Chairman, President and CEO | Nov 23 | Option | 0 | 15,000 | 164,716 | 11/23/20 | |
LIPPS RANDALL A | Chairman, President.. Chairman, President and CEO | Nov 23 | Sell | 105.21 | 15,000 | 1,578,150 | 152,116 | 11/23/20 |
LIPPS RANDALL A | Chairman, President.. Chairman, President and CEO | Nov 04 | Sell | 89.83 | 11,435 | 1,027,206 | 229,113 | 11/04/20 |
LIPPS RANDALL A | Chairman, President.. Chairman, President and CEO | Sep 16 | Sell | 75.59 | 15,143 | 1,144,659 | 240,548 | 09/16/20 |